Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement

Figures & data

Table I.  Patient's clinical evolution according to therapy.

Diagnosis	V.A.D. cycles n.	RT t.d. Gy	M.P. cycles n.	B.D. cycles n.	PS ECOG	Hb g/dl	PC p.b. ×10^9/l	PC b.m. %	s.M.I. Gλ g/dl	u.free λchain mg/l	Extram. mass	Bone lesions n.	s.ALP U/l	Response
PCL					3	10.3	6.2	81	2.81	1180	–	>3	86	–
	4				3	9.5	0.6	–	0.66	10.1	onset	>3	80	P.D.
		24			2	8.2	0.5	–	1.18	69.2	cl. imp.	>3	71	M.R.
			4		2	7.5	0.6	90	1.65	63.3	no change	>3	74	N.C.
				8	1	14.2	0	10	0.13	1.75	regression	>3	110	P.R.

Abbreviations: PCL: plasma cell leukemia; V.A.D.: vincristine/adryamicin/dexamethasone; RT: radiotherapy; t.d.: total dose; M.P.: melphalan/prednisone; B.D.: bortezomib/dexamethasone; ECOG PS: performance status according to Eastern Cooperative Oncology Group; Hb: hemoglobin; PC: plasma cells; p.b.: peripheral blood; b.m.: bone marrow; M.I.: monoclonal immunoglobulin; s.: serum; u.: urine; cl. imp.: clinical improvement; P.D.: progressive disease; M.R.: minimal response; N.C.: No Change; P.R.: partial response.

Figure 1.  Craniofacial computed tomography (CT) scan demonstrating an intracranial mass in our PCL patient.